National Institute of Dental and Craniofacial Research (NIDCR)

60 total trials 38 currently recruiting 20 completed

Trial Pipeline

RECRUITING Phase 2

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456

RECRUITING

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

NCT03602599

RECRUITING

Natural History of Craniofacial Anomalies and Developmental Growth Variants

NCT02639312

RECRUITING

Characterization of Diseases With Salivary Gland Involvement

NCT02327884

RECRUITING

Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal

NCT01805869

RECRUITING

Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)

NCT01568697

RECRUITING

The Pathogenesis and Natural History of Sjogren's Disease

NCT01425892

RECRUITING Phase 1

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

NCT00804154

RECRUITING

A Natural History Study of Bone and Mineral Disorders

NCT00024804

RECRUITING

Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome

NCT00001727

ACTIVE NOT RECRUITING Phase 1

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960

ACTIVE NOT RECRUITING Phase 2

Denosumab Treatment for Fibrous Dysplasia

NCT03571191

COMPLETED

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

NCT00565526

COMPLETED Phase 1

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

NCT00372320

COMPLETED

Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth

NCT00104026

COMPLETED

Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia

NCT00099762

COMPLETED Phase 2

Capsaicin to Control Pain Following Third Molar Extraction

NCT00088686

COMPLETED Phase 2

Synvisc to Treat Osteoarthritis of the Temporomandibular Joint

NCT00078351

COMPLETED

Studying Phosphorus Metabolism

NCT00066183

COMPLETED Phase 2

Magnets in the Treatment of Sciatica

NCT00044109

COMPLETED Phase 3

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

NCT00017927

COMPLETED

Pain Evaluation and Treatment

NCT00362167

COMPLETED Phase 2

Pain Treatment for Sciatica

NCT00009672

COMPLETED

Oral Manifestations of Aplastic Anemia

NCT00006300

COMPLETED Phase 2

Influence of Genetics in Pain Sensitivity

NCT00001956

COMPLETED Phase 2

Etanercept Therapy for Sjogren's Syndrome

NCT00001954

COMPLETED Phase 2

Celebrex for Pain Relief After Oral Surgery

NCT00006299

COMPLETED

Study of the Composition of Dental Plaque

NCT00001726

COMPLETED Phase 2

Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain

NCT00001725

COMPLETED

Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome

NCT00001973

COMPLETED Phase 2

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

NCT00001524

COMPLETED NA

Evaluation of Patients With Unusual Diagnostic or Treatment Considerations

NCT00001182

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 11
Phase 3 1

What the Pipeline for National Institute of Dental and Craniofacial Research (NIDCR) Shows

According to the ClinicalTrials.gov registry, National Institute of Dental and Craniofacial Research (NIDCR) is linked to 60 US clinical trials across every stage of research activity. Of those, 38 studies are currently recruiting — about 63% of the sponsor's indexed portfolio — and 20 are already marked complete, representing roughly 33% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for National Institute of Dental and Craniofacial Research (NIDCR) reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 14 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for National Institute of Dental and Craniofacial Research (NIDCR) is Sjogren's Syndrome with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial